Thanks for the explanation, and reaching out for the...

First 41 Last

Share
Profile

Follow
GooseMcghee

441 Posts.

58

02/09/20

17:33

Post #: 47031341
Share

Originally posted by Accumul8: ↑

All good @GooseMcghee. When I first read the table I was slightly perplexed as I was expecting one column of samples - like the results table from the 1st pilot run.
So rather than posting on the forum first thing I just went straight to the company for clarification rather than speculating.

Extract below.
"we are very happy with the results as you are correct that the average run is 99.995. This will be the product that we will send to third parties
The right hand side column is essentially trial material that we wanted to do on the kiln (hence we needed to do a larger number of samples). As we had them tested - we are obliged to release them (good or bad). So I wouldnt focus on the right hand side as being representative of our "standard product" - it is just learnings"

As per my previous post, running the pilot gives an opportunity not just to produce more HPA for interested counterparties... but it also gives a chance to trial a few things and phases of the flowsheet.

The next pilot run if the intention is to try and achieve higher grade, I will expect higher grade. If the plan changes, I will expect them to achieve whatever product grade it is they are trying to achieve.

Expand

Thanks for the explanation, and reaching out for the clarification.

For me that's great news, confirmed 99.995 is being achieved when they use their specified process.

I am comfortable with them experimenting with other methods and releasing, but it could certainly have been made clearer for people not scientifically minded, like myself.

Overall i'm still in the camp that this is very encouraging news.

FYI Price at posting: 8.5¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 55 more messages in this thread...

First 41 Last

Add CCM (ASX) to my watchlist

(20min delay)
Last 6.8¢		Change 0.001(1.49%)		Mkt cap ! $25.22M

Open	High	Low	Value	Volume
6.7¢	6.8¢	6.7¢	$7.47K	111.1K

Buyers (Bids)

No.	Vol.	Price($)
1	20000	6.2¢

Sellers (Offers)

Price($)	Vol.	No.
6.7¢	25000	1

View Market Depth

No.	Vol.	Price($)
1	20000	0.062
1	16666	0.060
1	14500	0.058
1	180	0.057
1	9109	0.055

Price($)	Vol.	No.
0.067	25000	1
0.068	68912	1
0.069	313335	5
0.070	274901	2
0.077	14000	1

Last trade - 14.40pm 07/10/2024 (20 minute delay)

CCM (ASX) Chart

Thanks for the explanation, and reaching out for the...

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks for the explanation, and reaching out for the...

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News